histamine
Approved
Mar 13, 1924
Histamine is a depressor amine derived by enzymatic decarboxylation of histidine. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and a centrally acting neurotransmitter. Phosphate salt of jistamine was used as a diagnostic aid for evaluation of gastric acid secretory function. In addition, this compound is used as a positive control in evaluation of allergenic (immediate hypersensitivity or "Type I") skin testing. In addition, histamine is being studied for treatment of multiple sclerosis. It was approved, that histamine physiological functions are mediated by four 7-transmembrane G protein-coupled receptors (H1R, H2R, H3R, H4R) that are all targets of pharmacological intervention. The receptors display molecular heterogeneity and constitutive activity. H1R antagonists are long known antiallergic and sedating drugs, whereas the H2R led to the development of H2R-antagonists that revolutionized stomach ulcer treatment. The H3R is an auto receptor and heteroreceptor providing negative feedback on histaminergic and inhibition on other neurons. The H4R occurs on immuncompetent cells and the development of anti-inflammatory drugs is anticipated. — NCATS
Clinical trial activity
57 trials · 38 clinical orgs · 4 marketing orgs
Earliest trial started Jul 1, 1998 (NCT00003991)
Timeline
1920s
- Mar 13, 1924
Jubilant Innovation Ltd. — Earliest FDA Approval
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Secondary Org
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Organization
1930s
- Apr 25, 1939
Eli Lilly — NDA Secondary Org
1950s
- Sep 29, 1950
ALK-Abello, S.A. — NDA Secondary Org
1990s
- Feb 14, 1992
Nielsen BioSciences, Inc. — NDA Secondary Org
- Jan 1, 1998
Earliest Phase 3 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
- Allergy and Immunology · Early Phase 1
- Asthma · Phase 2
- Back Pain · Phase 4
- Dermatology · Phase 2
- General Surgery · Phase 2
- Healthy Volunteers · Phase 1
- Immune System Diseases · Phase 2/Phase 3
- Immunosuppression Therapy · Phase 2
- Influenza, Human · Phase 2/Phase 3
- Kidney Neoplasms · Phase 2
- Knee Injuries · Phase 4
- Leukemia · Phase 3
- Leukemia, Myeloid, Acute · Phase 4
- Leukemia, Myelomonocytic, Chronic · Phase 1/Phase 2
- Low Back Pain · Phase 3
- Melanoma · Phase 3
- Migraine Disorders · Phase 4
- Multiple Sclerosis · Phase 2
- Myelodysplastic Syndromes · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 3
- Osteoarthritis, Knee · Phase 3
- Pain · Phase 4
- Pancreatic Neoplasms · Phase 2
- Respiratory Tract Infections · Phase 3
- Rhinitis, Allergic, Seasonal · Phase 2
Mechanism of action
- Histamine H1 receptorAGONIST
HRH1 agonist
Positive control for allegy test
- Unspecified targetOTHER
Topical analgesic
Mechanism_for_indication: Minor aches and pains.
- Unspecified targetOTHER
Immunoprotectant
Mechanism_for_indication: Acute myeloid leukemia.
Approval history
- approvedMar 13, 1924
Chemistry & pharmacology
SMILES
NCCc1c[nH]cn1.O=P(O)(O)O.O=P(O)(O)O- Mol. weight
- 307.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaHistamine dihydrochloride ↗
- ChEMBLCHEMBL3989520 ↗
- NCATS820484N8I3 ↗
- ChEMBLCHEMBL90 ↗
- WikipediaHistamine ↗
- ChEMBLCHEMBL1200801 ↗
- ChEMBLCHEMBL1554 ↗
- ChEMBLCHEMBL1533310 ↗
Also known as
- 1h-imidazole-4-ethanamine
- 1h-imidazole-4-ethanamine
- 2-(4-imidazolyl)ethylamine
- 2-(4-imidazolyl)ethylamine
- 4-imidazoleethylamine
- 4-imidazoleethylamine
- 5-imidazoleethylamine
- 5-imidazoleethylamine
- 5-imidazoleethylamine
- beta-aminoethylglyoxaline
- beta-aminoethylglyoxaline
- beta-aminoethylimidazole
- beta-aminoethylimidazole
- ceplene
- ceplene
- ceplene
- eramin
- ergamine
- ergotidine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine
- histamine acid phosphate
- histamine dihydrochloride
- histamine dihydrochloride
- histamine dihydrochloride
- histamine dihydrochloride
- histamine dihydrochloride
- histamine dihydrocloride
- histamine dihydrocloride
- histamine diphosphate
- histamine diphosphate
- histamine glutarimide
- histamine phosphate
- histamine phosphate
- histamine phosphate
- histamine phosphate
- histamine phosphate
- histamine phosphate
- histamine phosphate
- positive skin test control-histamine
- theramine
- theramine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07255092 | N/A | Dec 1, 2025 | Aalborg University |
| NCT07203274 | N/A | Dec 1, 2025 | Aalborg University |
| NCT07247695 | N/A | Nov 3, 2025 | Aalborg University |
| NCT07122973 | N/A | Sep 17, 2025 | Aalborg University |
| NCT06503510 | N/A | Oct 1, 2024 | Aalborg University |
| NCT06503523 | N/A | Sep 1, 2024 | Aalborg University |
| NCT06245564 | N/A | Aug 20, 2024 | Aalborg University |
| NCT06470737 | N/A | Jul 1, 2024 | Aalborg University |
| NCT06328543 | N/A | Jul 1, 2024 | Aalborg University |
| NCT06340438 | N/A | Apr 27, 2024 | Aalborg University |
| NCT05810792 | Phase 2 | Apr 1, 2024 | University of Gothenburg |
| NCT06328530 | N/A | Apr 1, 2024 | Aalborg University |
| NCT06154824 | N/A | Dec 15, 2023 | Aalborg University |
| NCT06081946 | N/A | Dec 15, 2023 | Aalborg University |
| NCT06379542 | Phase 3 | Dec 4, 2023 | Valenta Pharm JSC |
| NCT06081998 | N/A | Nov 1, 2023 | Aalborg University |
| NCT05558462 | N/A | Aug 22, 2022 | Valenta Pharm JSC |
| NCT05294250 | Phase 1 | Feb 1, 2022 | Valenta Pharm JSC |
| NCT04676763 | N/A | Feb 4, 2021 | GlaxoSmithKline |
| NCT04711044 | N/A | Feb 1, 2021 | Aalborg University |
Organizations
Research & Development (38)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aalborg University | Academic/Hospital | 24 | 24 | 1 | 2018 |
| Targeted Medical Pharma | For profit | 4 | 4 | 2 | 2009 |
| University of Gothenburg | Academic/Hospital | 3 | 1 | 2 | 2009 |
| Valenta Pharm JSC | For profit | 3 | 3 | 3 | 2022 |
| EpiCept Corporation | For profit | 2 | 0 | 2 | 2009 |
| EURRUS Biotech GmbH | For profit | 2 | 1 | 2 | 2016 |
| Maxim Pharmaceuticals | For profit | 2 | 2 | 1 | 1998 |
| Pharmenterprises LLC | For profit | 2 | 2 | 2 | 2015 |
| University of California, Los Angeles | Academic/Hospital | 2 | 0 | 2 | 2002 |
| Amphastar Pharmaceuticals | For profit | 1 | 1 | 1 | 2012 |
| Andrews-Paulos Research & Education Institute | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Apimeds | For profit | 1 | 1 | 1 | 2013 |
| BioHealthonomics Inc. | For profit | 1 | 1 | 1 | 2015 |
| Dynavax Technologies Corporation | For profit | 1 | 1 | 1 | 2006 |
| Free University of Brussels | Academic/Hospital | 1 | 1 | 1 | 2013 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2021 |
| Government of Russia | Government | 1 | 1 | 1 | 2020 |
| Groupe Francophone des Myelodysplasies | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Guangzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| Immune Tolerance Network | Academic/Hospital | 1 | 0 | 1 | 2011 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ALK-Abello, S.A. | For profit | NDA2 | Sep 29, 1950 |
| Eli Lilly | For profit | NDA2 | Apr 25, 1939 |
| Jubilant Innovation Ltd. | For profit | NDA2 | Mar 13, 1924 |
| Jubilant Innovation Ltd. | For profit | NDA | Mar 13, 1924 |
| Nielsen BioSciences, Inc. | For profit | NDA2 | Feb 14, 1992 |